How is CagriSema different from tirzepatide (Mounjaro, Zepbound)?

Both combine two hormone actions, but different ones. Tirzepatide pairs GIP with GLP-1. CagriSema pairs amylin, through the drug cagrilintide, with GLP-1, through semaglutide. Amylin is the distinct ingredient. In the one head-to-head trial, tirzepatide produced somewhat more weight loss, so CagriSema's difference is its mechanism rather than higher efficacy.

How much weight do you lose on CagriSema?

In its main trial, people with obesity and without diabetes lost about 22.7% of their body weight over 68 weeks, or about 20% counting everyone assigned to it. In people who also had type 2 diabetes, the figure was about 15.7%. These are strong results, among the highest for any weight-loss drug, though the obesity number came in below the roughly 25% the company had signaled.

Is CagriSema better than Ozempic or Wegovy?

For weight loss, yes, it does more than semaglutide alone: in its trial, the combination reached about 22.7% versus about 16% for semaglutide by itself. That makes sense, since CagriSema contains semaglutide plus a second drug. Whether the added benefit is worth the added complexity and cost, once it is approved and priced, is the practical question.

Is CagriSema FDA-approved?

No. As of mid-2026 it is under FDA review, having been submitted in late 2025, with a decision expected later in the year. It cannot be prescribed yet. Any product marketed as CagriSema before approval would be outside the regulated system and should be avoided.

How is CagriSema different from tirzepatide (Mounjaro, Zepbound)?

Both combine two hormone actions, but different ones. Tirzepatide pairs GIP with GLP-1. CagriSema pairs amylin, through the drug cagrilintide, with GLP-1, through semaglutide. Amylin is the distinct ingredient. In the one head-to-head trial, tirzepatide produced somewhat more weight loss, so CagriSema's difference is its mechanism rather than higher efficacy.

How much weight do you lose on CagriSema?

In its main trial, people with obesity and without diabetes lost about 22.7% of their body weight over 68 weeks, or about 20% counting everyone assigned to it. In people who also had type 2 diabetes, the figure was about 15.7%. These are strong results, among the highest for any weight-loss drug, though the obesity number came in below the roughly 25% the company had signaled.

Is CagriSema better than Ozempic or Wegovy?

For weight loss, yes, it does more than semaglutide alone: in its trial, the combination reached about 22.7% versus about 16% for semaglutide by itself. That makes sense, since CagriSema contains semaglutide plus a second drug. Whether the added benefit is worth the added complexity and cost, once it is approved and priced, is the practical question.

Is CagriSema FDA-approved?

No. As of mid-2026 it is under FDA review, having been submitted in late 2025, with a decision expected later in the year. It cannot be prescribed yet. Any product marketed as CagriSema before approval would be outside the regulated system and should be avoided.

CagriSema (Cagrilintide + Semaglutide): The Amylin Combo | Philadelphia

TL;DR30-second take

CagriSema is an investigational once-weekly injection from Novo Nordisk that combines two gut-hormone drugs: cagrilintide, a long-acting form of the satiety hormone amylin, and semaglutide, the GLP-1 drug in Ozempic and Wegovy. Pairing amylin with GLP-1 is a different approach from tirzepatide, which pairs GIP with GLP-1. In its main trial it produced about 22.7% weight loss over 68 weeks, a strong result, though below the 25% the company had hoped for, and in a head-to-head trial it did not prove as good as tirzepatide. It is not yet FDA-approved; the company filed for approval in late 2025.

TL;DR: CagriSema is an investigational once-weekly injection from Novo Nordisk that combines two drugs in one shot: cagrilintide, a long-acting version of the satiety hormone amylin, and semaglutide, the GLP-1 drug behind Ozempic and Wegovy. Pairing amylin with GLP-1 is a different two-hormone strategy from tirzepatide, which pairs GIP with GLP-1. In its main obesity trial it produced about 22.7% weight loss over 68 weeks, a strong result that nonetheless came in below the 25% the company had signaled, and in the one head-to-head trial it did not prove as good as tirzepatide. It is not yet FDA-approved; Novo filed for approval in late 2025, with a decision expected later in 2026. Its distinction is the amylin mechanism rather than a clear efficacy lead.

What is CagriSema, and how is it different from tirzepatide?

CagriSema is a single weekly injection that carries two active drugs. The first is semaglutide, the familiar GLP-1 receptor agonist that quiets appetite and slows the stomach. The second is cagrilintide, a long-acting analog of amylin, a hormone your pancreas releases alongside insulin that signals fullness, slows stomach emptying, and works in a part of the brainstem to curb eating. Putting the two together is the whole idea: two different satiety hormones, pushing on appetite through separate paths.

That makes CagriSema a different kind of combination from the other two-hormone drugs. Tirzepatide pairs GIP with GLP-1; retatrutide adds glucagon on top of those two. CagriSema instead pairs amylin with GLP-1, which is why its mechanism is often described as the novel part. Amylin as a target is not brand new: an older, short-acting amylin drug called pramlintide has been used at mealtimes in diabetes for years. What is new is a long-acting amylin analog that can be given once a week and combined with a GLP-1 in a single shot.

How much weight do people lose on CagriSema?

In REDEFINE 1, its main phase 3 trial in adults with obesity and without diabetes, CagriSema produced about 22.7% weight loss over 68 weeks, compared with a small amount on placebo.¹ For context, in the same trial semaglutide alone produced about 16% and cagrilintide alone about 12%, so the combination did more than either piece. A companion trial in people who also had type 2 diabetes, REDEFINE 2, showed a more modest 15.7%, which is the usual pattern, since weight loss tends to be smaller in diabetes.

That 22.7% is a strong number, among the highest for any weight-loss drug. Read it in context, though. The figure is the result for people who stayed fully on treatment; counting everyone assigned to the drug, the average was closer to 20%. And the number came in below the roughly 25% the company had pointed to beforehand, which is why a strong result was received as a letdown when it was announced. It is a good reminder that expectations, as much as the data, shape how a drug is judged.

Does CagriSema beat the other weight-loss drugs?

This is where a recent trial matters, and where accuracy matters. For a while, CagriSema's roughly 22 to 23% could be compared only loosely against tirzepatide's roughly 20 to 21% from separate trials, and the two looked to be in the same range. Then came REDEFINE 4, a head-to-head trial that pitted CagriSema directly against tirzepatide.

In that trial, reported in early 2026, CagriSema did not prove as good as tirzepatide. It aimed to show it was at least non-inferior, and it missed that goal: tirzepatide produced more weight loss, about 25.5% versus 23% for CagriSema in people who stayed on treatment. The result was close, and CagriSema is clearly a strong drug, but the head-to-head did not go its way. So the accurate summary is that CagriSema is a powerful new option whose main distinction is its amylin mechanism, rather than a drug that has been shown to beat the best injectable already available.

Is CagriSema approved, and what is its status?

Not yet. As of mid-2026, CagriSema is investigational: Novo Nordisk submitted it to the FDA in late 2025 for weight management, and a decision is expected later in 2026. So it is not something a doctor can prescribe today, and any version offered outside a trial or the eventual approved product should be treated with the same caution as any unapproved drug.

Its evidence, like that of the other new agents, rests on weight and blood sugar. CagriSema has no completed cardiovascular-outcomes trial, so there is no proof yet that it prevents heart attacks, strokes, or death. A large outcomes trial, REDEFINE 3, is underway in people with heart disease but has not reported. The semaglutide half of the combination does have that kind of proof on its own, from the SELECT trial, but the combination as a product has not been tested for hard outcomes yet.

What are the side effects?

They are the familiar effects of this drug class, centered on the gut: nausea, vomiting, and diarrhea, usually worst while the dose is being raised and easing over time. Adding the amylin component to a GLP-1 has not clearly changed that profile in either direction; the tolerability looks broadly in line with the GLP-1 drugs. As with the whole class, the side effects are the main reason some people stop, and slow dose escalation is the usual way to manage them. Because CagriSema is not yet approved, its full labeled cautions will be set when the FDA completes its review.

Guidance from the Clinic

"CagriSema is an interesting drug, and I am watching it closely, but I want patients to hear the full version rather than the headline. The good news is that it works well, north of 20% weight loss, and it does it with a new mechanism, the amylin pathway, which gives us another lever and another option if the others do not suit someone. The tempering news is twofold: it came in under the expectations that were set for it, and when it went head-to-head against tirzepatide, it did not come out ahead. So I do not think of it as a leap past what we have; I think of it as a strong addition to the toolbox with a distinct way of working. And it is not approved yet, so for now it is a drug to understand and follow rather than one I can offer. When it clears review, I will use it where its mechanism fits the patient."

Key Takeaways

CagriSema is an investigational once-weekly injection combining cagrilintide, a long-acting amylin analog, with semaglutide, a GLP-1 drug, pairing two satiety hormones in one shot.
Its combination differs from tirzepatide (GIP plus GLP-1) and retatrutide (a triple agonist); amylin is the distinct component.
In its main trial it produced about 22.7% weight loss over 68 weeks (about 20% counting everyone), and about 15.7% in people with type 2 diabetes, strong results that came in below the roughly 25% expected.
In the one head-to-head trial, REDEFINE 4, it did not prove as good as tirzepatide, which produced more weight loss, so its distinction is the amylin mechanism rather than a clear efficacy lead.
As of mid-2026 it is not FDA-approved (filed in late 2025, decision expected later in 2026) and has no cardiovascular-outcome data yet.

Tirzepatide (Zepbound, Mounjaro) - the injectable CagriSema was measured against
Retatrutide: The Triple Agonist - the other emerging combination, adding glucagon
Survodutide (GLP-1/Glucagon) - the glucagon dual agonist built for the liver
Amycretin (Amylin/GLP-1) - the single-molecule amylin/GLP-1 drug, in a pill and a shot
Orforglipron (Foundayo) - the emerging oral GLP-1 pill
Ozempic vs Metformin - where semaglutide, CagriSema's GLP-1 half, fits
Medical Weight Loss - building a durable plan around these drugs

Scientific References

Garvey WT, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2025;393(7):635-647.

Fishtown Medicine | Metabolism

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Deep-Dive Questions

Amylin is a hormone your pancreas releases together with insulin after you eat. It promotes fullness, slows how fast the stomach empties, and acts on the brainstem to reduce further eating, complementing insulin's job of handling the glucose. GLP-1, the other hormone in the combination, also curbs appetite and slows the stomach, but through a partly separate pathway. The logic of combining them is that two satiety signals pressing on appetite from different directions may add up to more weight loss than either alone, which is what the trial showed. It is the same additive logic behind tirzepatide, using a different second hormone.

Because expectations had been set higher. The company had pointed toward roughly 25%, and investors and analysts had priced that in, so 22.7% read as a shortfall even though it is one of the largest weight-loss figures ever reported for a drug. The later head-to-head against tirzepatide deepened the impression, since CagriSema did not prove at least as good as the drug it was meant to challenge. None of this makes CagriSema a weak drug; it makes it a strong drug that was measured against very high hopes and a very strong competitor. The gap between a good result and a disappointing reception is often about the story told beforehand.

For almost everyone, the answer is to act now with an approved option rather than wait. CagriSema is not available, its approval and price are not settled, and the drugs already on the market, semaglutide and tirzepatide, produce excellent results today. If you and your physician decide a GLP-1 or dual agonist fits you, starting now and reassessing later is usually wiser than delaying care for a drug that may or may not offer you an advantage once it arrives. When CagriSema is approved, its place will become clearer, and switching is always possible.

It might, and that is part of why the class is interesting, but the evidence is still young. In theory, amylin's action on satiety and its effect on how the body handles meals could complement GLP-1 in ways that help with appetite control or with preserving the quality of weight lost, and amylin analogs are being studied both alone and in combinations. For now, though, the fair position is that CagriSema's proven advantage over a GLP-1 alone is more weight loss, and the deeper mechanistic benefits of amylin remain a promising idea under study rather than an established fact.

Ready when you are